Form

Gritstone bio Announces Proposed Public Offering

Retrieved on: 
Monday, April 1, 2024
Vanderbilt Avenue, TD Securities, Form, Telephone, Sale, Attention, Gritstone bio, Form S-3, Vaccine, Equity capital markets, Evercore, Security (finance)

All of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by Gritstone bio.

Key Points: 
  • All of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by Gritstone bio.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • TD Cowen and Evercore ISI are acting as the joint book-running managers for the proposed offering.
  • The securities are being offered by Gritstone bio pursuant to a registration statement on Form S-3 (File No.

Applied UV, Inc. Announces Closing of $2.76 Million Registered Direct and Private Placement

Retrieved on: 
Monday, April 1, 2024
Common stock, Private, Exercise, Form, Telephone, Common, Sale, Attention, Share (finance), Form S-3, Prospectus, P.C, Security (finance)

The Company issued shares of common stock of the Company (“Common Stock”) and pre-funded warrants (“Pre-Funded Warrants”) in a registered direct offering.

Key Points: 
  • The Company issued shares of common stock of the Company (“Common Stock”) and pre-funded warrants (“Pre-Funded Warrants”) in a registered direct offering.
  • In a concurrent private placement, the Company also issued common warrants (“Common Warrants”) to the same investors.
  • Aggregate gross proceeds to the Company from both transactions were approximately $2.76 million.
  • The registered direct offering was being made pursuant to an effective shelf registration statement on Form S-3 (No.

U-BX Technology Ltd. Announces Closing of $10 Million Initial Public Offering

Retrieved on: 
Monday, April 1, 2024
EF Hutton, Common stock, Madison Avenue, Offering, Form, Telephone, Winston & Strawn, Sale, Insurance, Prospectus, ATTN:, Security (finance)

Beijing, April 01, 2024 (GLOBE NEWSWIRE) -- U-BX Technology Ltd. (the “Company” or “UBXG”), an artificial intelligence-driven value-added services and products provider to insurance carriers, today announced the closing of its initial public offering (the "Offering") of 2,000,000 ordinary shares (the "Ordinary Shares") at an initial public offering price of $5.00 per share for total gross proceeds of $10,000,000, before deducting underwriting discounts and other offering expenses.

Key Points: 
  • Beijing, April 01, 2024 (GLOBE NEWSWIRE) -- U-BX Technology Ltd. (the “Company” or “UBXG”), an artificial intelligence-driven value-added services and products provider to insurance carriers, today announced the closing of its initial public offering (the "Offering") of 2,000,000 ordinary shares (the "Ordinary Shares") at an initial public offering price of $5.00 per share for total gross proceeds of $10,000,000, before deducting underwriting discounts and other offering expenses.
  • The Offering closed on April 1, 2024, and the Ordinary Shares began trading on Nasdaq Capital Market on March 28, 2024, under the ticker symbol "UBXG".
  • The Company has granted EF Hutton LLC (“EF Hutton”), the underwriter, an option to purchase up to an additional 300,000 Ordinary Shares at the public offering price, less underwriting discounts, to cover the over-allotments, if any, exercisable within 45 days from the closing date of the Offering.
  • EF Hutton acted as the sole bookrunner for the Offering.

Vislink Reports Fourth Quarter and Full Year 2023 Financial and Operational Results - Update

Retrieved on: 
Monday, April 1, 2024
Olive, Solidified, Tax, Growth, Gateway Group, Original equipment manufacturer, Form, Software, Acquisition, BMS, AI, Security (finance), Investment, GAAP, Depreciation, OB, OpenText, Zoom Video Communications, Video game

Mt. Olive, NJ, April 01, 2024 (GLOBE NEWSWIRE) -- Vislink Technologies, Inc. (“Vislink” or the “Company”) (Nasdaq: VISL), a global technology leader in the capture, delivery, and management of high-quality, live video and associated data in the media and entertainment, public safety, and defense markets, today reported results for the fourth quarter and full year ended December 31, 2023. The Company will file the Form 10-K with the Securities and Exchange Commission by April 16, 2024.

Key Points: 
  • Increased Software and Services revenue to more than 10% of sales in 2023.
  • “2023 marked a pivotal year for Vislink, as we laid the groundwork for accelerated revenue growth and cash flow neutrality in 2024,” said Vislink CEO Mickey Miller.
  • Cash and short-term investments were $14.2 million at December 31, 2023, compared to $18.2 million at the end of the third quarter.
  • Management will host a conference call today, April 1, 2024, at 8:30 a.m. Eastern Time to discuss its financial results for the fourth quarter and full year ended December 31, 2023.

Vislink Reports Fourth Quarter and Full Year 2023 Financial and Operational Results

Retrieved on: 
Monday, April 1, 2024
Olive, Solidified, Tax, Growth, Gateway Group, Original equipment manufacturer, Form, Software, Acquisition, BMS, AI, Security (finance), Investment, GAAP, Depreciation, OB, OpenText, Zoom Video Communications, Video game

Mt. Olive, NJ, April 01, 2024 (GLOBE NEWSWIRE) -- Vislink Technologies, Inc. (“Vislink” or the “Company”) (Nasdaq: VISL), a global technology leader in the capture, delivery, and management of high-quality, live video and associated data in the media and entertainment, public safety, and defense markets, today reported results for the fourth quarter and full year ended December 31, 2023. The Company will file the Form 10-K with the Securities and Exchange Commission by April 16, 2024.

Key Points: 
  • Increased Software and Services revenue to more than 10% of sales in 2023.
  • “2023 marked a pivotal year for Vislink, as we laid the groundwork for accelerated revenue growth and cash flow neutrality in 2024,” said Vislink CEO Mickey Miller.
  • Cash and short-term investments were $14.2 million at December 31, 2023, compared to $18.2 million at the end of the third quarter.
  • Management will host a conference call today, April 1, 2024, at 8:30 a.m. Eastern Time to discuss its financial results for the fourth quarter and full year ended December 31, 2023.

Financial Institutions, Inc. Announces Sale of the Assets of SDN Insurance Agency to NFP

Retrieved on: 
Monday, April 1, 2024
8-K, Financial institution, Five Star Bank, PC, Growth, Form, Bank, Sale, LLP, Security (finance), NFP, Insurance

As part of the transaction, the SDN team joins NFP, including President William E. Gallagher.

Key Points: 
  • As part of the transaction, the SDN team joins NFP, including President William E. Gallagher.
  • “In the nearly 10 years since we entered the insurance space, it has proven to be a valuable line of business that supported revenue diversification.
  • SDN is a full-service insurance agency serving business and personal insurance customers.
  • “In its 100-year history, SDN has established itself as a well-respected partner to commercial and personal insurance customers throughout Western New York,” said Mr. Gallagher.

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, April 1, 2024
Research, Lung cancer, Medical school, Shanghai Jiao Tong University, Carcinoma, Fast track (FDA), Form, Patient, G&A, School, IPO, Hope, Security (finance), Guggenheim Partners, Investment, Platinum, Interim, Genelux Corporation, FDA, Pharmaceutical industry

WESTLAKE VILLAGE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2023 financial results and business updates.

Key Points: 
  • – $23.2 million in cash, cash equivalents and short-term investments –
    WESTLAKE VILLAGE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2023 financial results and business updates.
  • Currently, 21 sites have been activated to enroll patients with additional sites identified and in various stages of activation ( NCT05281471 ).
  • Genelux and our partner Newsoara co-sponsor the trial, which is being conducted by Newsoara in greater China.
  • Cash, cash equivalents and short-term investments were $23.2 million as of December 31, 2023 compared to $0.4 million on December 31, 2022.

Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Monday, April 1, 2024
3rd Floor, Exercise, Form, SAN, Sale, Security (finance), Prospectus, Investment, Therapy, Regulation D

(Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 5,454,548 shares of the Company’s common stock at an offering price of $1.10 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

Key Points: 
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 5,454,548 shares of the Company’s common stock at an offering price of $1.10 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.
  • In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 5,454,548 shares of common stock.
  • The closing of the offering is expected to occur on or about April 3, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to Biora from this offering are expected to be approximately $6 million, before deducting the placement agent’s fees and other offering expenses.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Children’s Place, and Ventyx and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, April 1, 2024
Psoriasis, Form, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Prospectus, Complaint, P.C, File, Register

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.

Key Points: 
  • On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.
  • Therein, the Company revealed that it now expected fourth quarter net sales between $454 million and $456 million, falling short of previously issued guidance.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • As of the time the Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTYX

Retrieved on: 
Sunday, March 31, 2024
Psoriasis, Register, Form, District court, Defendant, News, Ext, LLP, IPO, Security (finance), Inflammation, Plaque, Prospectus, Complaint, File, Pomerantz, Action Replay, Court, Person

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.